PharmaLive (press release) (subscription) ... Year in Review report. “But with biotech valuations sky high, it is clear that any acquirer will have to be prepared to pay top dollar to access many of the drug developers that investors have become so excited about.” ..... But a number of drug ...
InvestorIdeas.com (press release) Is the Parkinson's disease product, the selective adenosine 2a receptor (A2A) antagonist tozadenant (SYN115), driving any value here? CG: Yes. Because Selincro is licensed to Lundbeck, the key operational focus of Biotie is tozadenant, which is, as you ... and more »
